BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ARTES Biotechnology and m2p-labs Join Forces


2/26/2008 9:05:35 AM

Langenfeld / Aachen, 25. February 2008 – ARTES Biotechnology GmbH (Langenfeld) and m2p-labs GmbH (Aachen) announced today the start of a long-term collaboration in clone screening and media optimisation. The two companies combine their proprietary technologies and know-how in yeast expression and high throughput fermentation. In this exclusive collaboration the two companies offer strain selection, physiological characterization and media optimization with the two yeast systems Hansenula polymorpha and Arxula adeninivorans.

The combination of this high-productive expression systems and the powerful BioLector screening tool provide much more physiological data (all common fermentation parameters) at a high throughput level in screening and early bioprocess development. Comparative and quantitative online data of different clones and media under a broad range of engineered process conditions allow know-ledge based decisions in the micro scale, reduces costs and time lines and overcome scale up problems. Both companies are convinced that their clients will profit from this new technology offer by reduced time lines in strain and process development, the availability of new carbon sources and more productive clones and culture conditions. The overall benefit will be in addition to the best expression system also the most productive bioprocess.

ARTES Biotechnology GmbH – www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production from yeast expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha and Arxula adeninivorans. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld near Duesseldorf. The company focuses on contract R&D for white and red biotechnology products.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES